Studies, Synthesis, Characterization and Studies of Levosulpiride Derivatives

Overview

Journal Future Med Chem

Specialties Chemistry
Pharmacy

Date 2024 Oct 15

PMID 39404461

Authors

Muhammad Toseef Akram

Mohsin Abbas Khan

Irshad Ahmad

Farhat Ullah

Muhammad Rizwan Khan

Zarmeena Yasmeen

Khalil Ahmad

Breena Breena

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most recurring cancer among females and is being diagnosed as a major cause of death among women. Levosulpiride Schiff base derivatives were synthesized and analyzed by physical and spectral (FTIR, H-NMR, C-NMR) analysis. MTT assay against MCF-7 (human breast cancer cell line), scavenging activity and Molecular docking against receptors 1M17, 3PP0, 3IOK and 4KIK along ADME pharmacokinetic studies were performed. L1 and L3 synthesized derivatives have revealed better percent cell viability and inhibitory concentration (IC) with scavenging activity as of the parent compound. L1, L3 and L9 revealed significant docking scores compared with standard drugs. Most of the derivatives showed strong pharmacokinetic profiles while no drug crossed blood-brain barrier. The newly synthesized L1 and L3 levosulpiride-derived compounds have demonstrated promising anticancer properties against breast cancer cells.

References

Moore H, Unger J, Phillips K, Boyle F, Hitre E, Porter D . Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015; 372(10):923-32. PMC: 4405231. DOI: 10.1056/NEJMoa1413204. View

Costa B, Amorim I, Gartner F, Vale N . Understanding Breast cancer: from conventional therapies to repurposed drugs. Eur J Pharm Sci. 2020; 151:105401. DOI: 10.1016/j.ejps.2020.105401. View

Ye F, Dewanjee S, Li Y, Jha N, Chen Z, Kumar A . Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023; 22(1):105. PMC: 10324146. DOI: 10.1186/s12943-023-01805-y. View

Pernas S, Tolaney S . HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019; 11:1758835919833519. PMC: 6425535. DOI: 10.1177/1758835919833519. View

Li Y, Zheng J, Deng Y, Deng X, Lou W, Wei B . Global Burden of Female Breast Cancer: Age-Period-Cohort Analysis of Incidence Trends From 1990 to 2019 and Forecasts for 2035. Front Oncol. 2022; 12:891824. PMC: 9218744. DOI: 10.3389/fonc.2022.891824. View

Hamad A, Chen Y, Khan M, Jamshidi S, Saeed N, Clifford M . Schiff bases of sulphonamides as a new class of antifungal agent against multidrug-resistant Candida auris. Microbiologyopen. 2021; 10(4):e1218. PMC: 8301596. DOI: 10.1002/mbo3.1218. View

Ledeboer M, Pierce A, Duffy J, Gao H, Messersmith D, Salituro F . 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2. Bioorg Med Chem Lett. 2009; 19(23):6529-33. DOI: 10.1016/j.bmcl.2009.10.053. View

Ataollahi M, Sharifi J, Paknahad M, Paknahad A . Breast cancer and associated factors: a review. J Med Life. 2017; 8(Spec Iss 4):6-11. PMC: 5319297. View

Barok M, Joensuu H, Isola J . Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014; 16(2):209. PMC: 4058749. DOI: 10.1186/bcr3621. View

10.

Tanabe M . Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab after Anthracycline, Taxane, and Capecitabine. Case Rep Oncol. 2016; 9(2):422-426. PMC: 5043245. DOI: 10.1159/000447770. View

11.

Wang X, Ren J, Zhang J, Yan Y, Jiang N, Yu J . Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). Clin Transl Oncol. 2015; 18(1):82-7. DOI: 10.1007/s12094-015-1339-2. View

12.

Heo J, Yi H, Fava M, Mischoulon D, Kim K, Yoon S . Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study. Psychiatry Investig. 2017; 14(4):491-498. PMC: 5561408. DOI: 10.4306/pi.2017.14.4.491. View

13.

Chang A, Wu Q, Jenkins I, Specht J, Gadi V, Gralow J . Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. Clin Breast Cancer. 2017; 18(1):e143-e149. DOI: 10.1016/j.clbc.2017.10.005. View

14.

Liu S, Misquitta Y, Olland A, Johnson M, Kelleher K, Kriz R . Crystal structure of a human IκB kinase β asymmetric dimer. J Biol Chem. 2013; 288(31):22758-67. PMC: 3829360. DOI: 10.1074/jbc.M113.482596. View

15.

Purawarga Matada G, Dhiwar P, Abbas N, Singh E, Ghara A, Das A . Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer. J Biomol Struct Dyn. 2021; 40(13):6183-6192. DOI: 10.1080/07391102.2021.1877823. View

16.

Gerber D . Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008; 77(3):311-9. View

17.

Ciruelos Gil E . Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014; 40(7):862-71. DOI: 10.1016/j.ctrv.2014.03.004. View

18.

Ho G, Woodward N, Coward J . Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol. 2016; 102:37-46. DOI: 10.1016/j.critrevonc.2016.03.014. View

19.

Spiegel M . Current Trends in Computational Quantum Chemistry Studies on Antioxidant Radical Scavenging Activity. J Chem Inf Model. 2022; 62(11):2639-2658. PMC: 9198981. DOI: 10.1021/acs.jcim.2c00104. View

20.

Harbeck N, Beckmann M, Rody A, Schneeweiss A, Muller V, Fehm T . HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel). 2014; 8(1):49-55. PMC: 3971793. DOI: 10.1159/000346837. View